

# Aberrant receptor expression in thyroid tissue: A role in the pathogenesis of multinodular goiter?

## A pilot study

Published: 09-10-2012

Last updated: 01-05-2024

**Objective**The main goal of this investigation is to evaluate the thyroid hormone response in patients with TMNG and control subjects in response to various pharmacological and physiological stimuli, administered according to the dynamic exposure test...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Thyroid gland disorders
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON40001

### Source

ToetsingOnline

### Brief title

Aberrant receptor expression in thyroid tissue

### Condition

- Thyroid gland disorders

### Synonym

(Toxic) Multinodular Goiter

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** 1. (Toxic) Multinodular Goiter, 2. ACTH independent macronodular adrenal hyperplasia, 3. Aberrant receptor expression, 4. Lacroix protocol

## Outcome measures

### Primary outcome

Endpoint

The % increase in total T4, T3 and Free T4, defined as:  $([T4/T3/FT4 \text{ max} * T4/T3/FT4 \text{ at baseline}] / T4/T3/FT4 \text{ at baseline}) \times 100\%$

### Secondary outcome

none reported

## Study description

### Background summary

Aberrant receptor expression in thyroid tissue: A role in the pathogenesis of multinodular goiter? A pilot study

Background

Toxic Multinodular Goiter (TMNG): Two key factors in the development of TMNG are hyperplasia \* i.e. nodule and goiter - and hyperfunction \* i.e. thyroid autonomy. Although TMNG is associated with iodine deficiency, this factor alone can not explain sufficiently the pathogenesis of TMNG, since TMNG also occurs in individuals from iodine sufficient areas. So the underlying mechanism of both hyperplasia and hyperfunction is not yet completely understood.

ACTH-independent macronodular adrenal hyperplasia (AIMAH): Recent research has shown that the enhanced cortisol production in patients with AIMAH, despite a suppressed ACTH, is regulated by hormones other than ACTH, via the aberrant expression of several G-protein coupled hormone receptors mimicking the cellular events that in normal circumstances are triggered by ACTH receptors.

AIMAH and TMNG: similarities: Two important similarities can be noted in the abovementioned diseases: 1) Hyperfunction: overproduction of cortisol and thyroid hormone, respectively and 2) Hyperplasia: gradual development of macronodular hyperplasia, overpassing the midline \* i.e. bilateral hyperplasia

in the adrenal glands and multinodular goiter in the whole thyroid gland.

## **Study objective**

### **Objective**

The main goal of this investigation is to evaluate the thyroid hormone response in patients with TMNG and control subjects in response to various pharmacological and physiological stimuli, administered according to the dynamic exposure test as described by Lacroix.

## **Study design**

### **Design**

After an overnight fast, patients will visit the research unit on three separate days, between each day a one-week interval, in order to prevent uncertainty about the agent causing the peak in FT4 and T3. We will evaluate the thyroid response to three different stimuli that we think are most likely involved in the pathogenesis of TMNG. Starting 30 minutes after administration of each stimulatory agent \* GnRH, metoclopramide and a mixed meal - blood will be drawn every 30 minutes for determination of the thyroid hormone response \* i.e. T4, T3, TSH and FT4 \* in 10 drug naive patients with toxic multinodular goiter and in 5 age and sex matched healthy controls.

On each testing day, blood is sampled at baseline and once every 30 minutes, starting 30 minutes after administration of the stimulatory agent/ mixed meal until 5 hours thereafter. The following thyroid hormones will be measured: FT4, T3, total T4 and TSH, using routine immunoassay: T4 and T3 with in-house RIA, FT4 and TSH by a commercial (Delfia, PerkinElmer) method.

## **Intervention**

no intervention

## **Study burden and risks**

### **Burden for the participants**

The risk for participants is judged to be minor. Participation mainly requires an investment of time, undergoing insertion of an intravenous catheter for blood sampling and administration of a single dose of 10 mg metoclopramide and a single dose of 100 mcg gonadorelin. We do not expect any side effects from a single gift of these agents. Side effects of metoclopramide are dose-related and include drowsiness, diarrhea and extrapyramidal symptoms, like rigidity of the muscles and tremor. These extrapyramidal symptoms disappear spontaneously after discontinuing the metoclopramide. For gonadorelin, short-term nausea, headache and abdominal pain have been described as side effects.

## Contacts

### Public

Academisch Medisch Centrum

Meibergdreef 9  
Amsterdam Zuid-Oost 1105 AZ  
NL

### Scientific

Academisch Medisch Centrum

Meibergdreef 9  
Amsterdam Zuid-Oost 1105 AZ  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

- \* Informed consent form signed
- \* Age 18 years and over
- \* Multinodular goiter, confirmed with thyroid ultrasound
- \* Subclinical hyperthyroidism, defined as TSH < 0.10 mE/l and free T4 within reference range [10.0 \* 23.0 pmol/l]
- \* T3 level within reference range, i.e. between 1.30 and 2.70 nmol/l

### Exclusion criteria

- \* Current use of antithyroid drugs
- \* Treatment with radioactive iodine in history

- \* Pregnancy. This condition may lead to subtle enlargement of the thyroid gland, secondary to iodine deficiency. All premenopausal female participants will undergo a \*-hCG-urine test before inclusion.
- \* Born and raised in iodine deficient areas, defined as the green and dark green fields in Figure 3 (protocol, p 13) .
- \* Any medication known to interfere with thyroid hormone metabolism or with the study medication, like amiodarone, beta blockers, neuroleptics, corticosteroids including inhalation steroids, antihistaminics
- \* Any condition that the investigator feels would interfere with trial participation or evaluation of results

## Study design

### Design

Study type:	Interventional
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Diagnostic

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	20-12-2012
Enrollment:	15
Type:	Actual

## Ethics review

Approved WMO	
Date:	09-10-2012
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	

Date:	08-01-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	18-02-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL40154.018.12